Khanyukov O. O., Pesotskaya L. A., Кrotova V. Yu., Panina S. S., Sapozhnychenko L. V

PROGNOSTIC VALUE OF CELLULAR CHANGES IN THE BLOOD TEST DURING COVID-19 INFECTION

---

Show/Download

About the author:

Khanyukov O. O., Pesotskaya L. A., Кrotova V. Yu., Panina S. S., Sapozhnychenko L. V

Heading:

LITERATURE REVIEWS

Type of article:

Scientific article

Annotation:

Changes in laboratory tests help in risk stratification and early adjustment of therapy in any pathology, COVID19 infection is no exception. Therefore, work on the systematization of hematological changes in COVID-19 infection, which have clinical prognostic value, deserves attention. Established that important biomarkers of the severity of COVID-19 infection are lymphopenia, primarily due to CD8 T-lymphocytes, neutrophilia, thrombocytopenia, decreased monocyte count, leukocytosis or leukopenia, and an increase in eosinophils. The progression of inflammation with a high risk of death in COVID-19 infection is associated with the following changes in a blood test: an increased ratio of neutrophils/lymphocytes, neutrophils/platelets; decrease in the ratio of the number of lymphocytes/ leukocytes, progression of lymphopenia, neutrophilia, decrease in eosinophils, progression of thrombocytopenia, anemia, increased distribution of erythrocytes by volume.

Tags:

Bibliography:

1. Lysenko DA, Andrushko II, Gunko IP. Hematologichni pokaznyky perefyrychnoi krovi yak factor prognozu u pathientiv z COVID-19 (Oglyad literatury). Bulletin of Vinnytsia National Medical University. 2021;25(1):175-179. DOI: 10.31393/reports-vnmedical-2021-25(1)-31. [in Ukrainian].
2. Wu C, Chen X, Cai Y, Jia’an Xia, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. DOI: 10.1001/jamainternmed.2020.0994.
3. Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-1720. DOI: 10.1056/NEJMoa2002032.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. DOI: 10.1001/jama. 2020.1585.
5. Agbuduwe C, Supratik B. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. Eur J Haematol. 2020 Nov;105(5):540-546. DOI: 10.1111/ejh.13491.
6. Urra JM, Cabrera CM, Porras L, Ródenasa I. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clin Immunol. 2020 Aug;217:108486. DOI: 10.1016/j.clim.2020.108486.
7. Sun DW, Zhang D, Tian RH, Yang Li, Wang YS, Cao J, et al. The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel? Clin Chim Acta. 2020 Sep;508:122-129. DOI: 10.1016/j.cca.2020.05.027.
8. Pozdnyakova O, Connell NT, Battinelli EM, Connors JM, Fell G, Kim AS. Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection. Am J Clin Pathol. 2021 Feb 11;155(3):364-375. DOI: 10.1093/ajcp/aqaa231.
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. DOI: 10.1016/S0140-6736(20)30183-5.
10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069. DOI: 10.1001/jama.2020.1585.
11. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. DOI: 10.1001/jamainternmed.2020.0994.
12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062. DOI: 10.1016/S0140-6736(20)30566-3.
13. Duarte FB, Lemes RPG, Duarte IA, Duarte BA, Duarte JVA. Hematological changes in Covid-19 infections. Rev Assoc Med Bras. 2020;66:99. DOI: 10.1590/1806-9282.66.2.99.
14. Gajendra S. Spectrum of hematological changes in COVID-19. Am J Blood Res. 2022;12(1):43-53. Available from: https://pubmed.ncbi. nlm.nih.gov/ 35291254/.
15. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020;95:E131-E134. DOI: 10.1002/ajh.25774.
16. Wang H, Zhang Y, Mo P, Liu J, Wang H, Wang F, et al. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19. Int Immunopharmacol. 2020;85:106683. DOI: 10.1016/j.intimp.2020.106683.
17. Marwah M, Marwah S, Blann A, Morrissey H, Ball P, Wandroo FA. Analysis of laboratory blood parameter results for patients diagnosed with COVID-19, from all ethnic group populations: a single centre study. Int J Lab Hematol. 2021;43:1243-1251. DOI: 10.1111/ijlh.13538.
18. Deng Y, Liu W, Liu K, Zhang S, Yang S, Tao Y, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133:1261-1267. DOI: 10.1097/CM9.0000000000000824.
19. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020 Jun 25;58(7):1063-1069. DOI: 10.1515/cclm-2020-0240.
20. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis 2020 Jul 28;71(15):762-768. DOI: 10.1093/cid/ciaa248.
21. Melnik AA. Nevirusologicheskie laboratornye marker v kontekste zabolevaniya COVID-19. Novyny medycyny ta farmacii. 2020;6.7(724.725):12-14. Dostupno: http://www.mif-ua.com/archive/article/49417.
22. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Jul;75(7):1730-1741. DOI: 10.1111/all.14238.
23. Fraissé M, Logre E, Mentec H, Cally R, Plantefève G, Contou D. Eosinophilia in critically ill COVID-19 patients: a French monocenter retrospective study. Crit Care. 2020; 24(1):635. DOI: 10.1186/s13054-020-03361-z.
24. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med. 2020;201:1372-1379. DOI: 10.1164/rccm.202003-0543OC.
25. Cavalcante-Silva LHA, Carvalho DCM, Lima ÉA, Galvão JGFM, de França da Silva JS, de Sales-Neto JM, et al. Neutrophils and COVID-19: the road so far. Int Immunopharmacol. 2021;90:107233. DOI: 10.1016/j.intimp.2020.107233.
26. Li Q, Cao Y, Chen L, Yu J, Wang H, He W, et al. Hematological features of individuals with COVID-19. Leukemia. Aug 2020;34(8):2163-72. DOI: 10.1038/s41375-020-0910-1.
27. Qu R, Ling Y, Zhang Y, Chen X, Li XM, Liu XY, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J. Med. Virol. 2020 Sep;92(9):1533-1541. DOI: 10.1002/jmv.25767.
28. Erdinc B, Sahni S, Gotlieb V. Hematological manifestations and complications of COVID-19. Adv Clin Exp Med. 2021;30:101-107. DOI: 10.17219/acem/130604.
29. Foy BH, Carlson JCT, Reinertsen E, Padros I Valls R, Pallares Lopez R, Palanques-Tost E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open. 2020;3:e2022058. DOI: 10.1001/jamanetworkopen.2020.22058.
30. Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol. 2020;190:29-31. DOI: 10.1111/bjh.16794.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 3, 170, 130-134 pages, index UDC 616.98:578.834COVID-19-091.8-074-037

DOI:

10.29254/2077-4214-2023-3-170-130-134